Key Takeaways
- • UC Davis is launching sector-specific spinout investment funds, beginning with a $25 million life sciences and healthcare fund (Investing in the Future of Medicine Fund) launched in April 2025, representing a strategic shift from its historical reliance on technology licensing revenue.
- • The university has partnered with HM Ventures (San Francisco-based VC firm) on the healthcare fund and signed a deal with The March Group (Davis-based VC) to establish a $10 million food and health spinout investment fund, signaling deepened ties with the venture capital ecosystem.
- • UC Davis is responding to declining traditional government funding under the new US administration by building proprietary investment mechanisms—a strategy increasingly adopted across US universities to directly capitalize on their own research and spinout companies.
- • This marks a fundamental operational change for the university, which historically eschewed equity stakes in spinouts despite geographic proximity to Bay Area venture capital, opting instead for passive licensing revenue models.
- • George Baxter, UC Davis's chief innovation and economic development officer, emphasized the strategic importance of direct investment capability: "We've never had a mechanism for investment into our own companies. This Investing in Future Medicine Fund will allow us to do that for the first time."
Summary
UC Davis is executing a strategic pivot toward direct venture capital engagement by launching sector-specific spinout investment funds designed to capitalize on research commercialization from within its own laboratories. The initiative marks a departure from the university's historical approach of generating returns exclusively through technology licensing agreements.
The university launched the Investing in the Future of Medicine Fund in April 2025, a $25 million dedicated vehicle for life sciences and healthcare spinouts. HM Ventures, a San Francisco-based venture capital firm, serves as a partner and investment committee member. UC Davis is simultaneously negotiating additional capital commitments from other venture firms and corporate investors to expand the healthcare fund's firepower. The university has also secured a partnership with The March Group, a Davis-based venture capital firm, to establish a complementary food and health accelerator and an associated $10 million spinout investment fund focused on food and health sector companies.
The timing reflects broader institutional dynamics across American higher education. UC Davis, like many US universities, is responding to reduced traditional government funding under the current administration by building proprietary investment infrastructure. By taking direct equity positions in spinout companies rather than limiting itself to licensing arrangements, the university can participate in long-term value creation from breakthrough research emerging from its laboratories.
George Baxter, the university's chief innovation and economic development officer, characterized the structural change as foundational: the Investing in the Future of Medicine Fund represents the institution's first formal mechanism for capital deployment into its own companies. This approach positions UC Davis to compete more effectively with peer institutions while leveraging its proximity to the Bay Area venture capital ecosystem, where the university historically maintained informal relationships but did not formally participate as an investor.
The strategy reflects a wider institutional recognition that direct equity participation in spinouts can generate superior returns compared to passive licensing models, while simultaneously strengthening the university's role in the regional innovation economy and creating employment and economic development opportunities in its local market.
The university launched the Investing in the Future of Medicine Fund in April 2025, a $25 million dedicated vehicle for life sciences and healthcare spinouts. HM Ventures, a San Francisco-based venture capital firm, serves as a partner and investment committee member. UC Davis is simultaneously negotiating additional capital commitments from other venture firms and corporate investors to expand the healthcare fund's firepower. The university has also secured a partnership with The March Group, a Davis-based venture capital firm, to establish a complementary food and health accelerator and an associated $10 million spinout investment fund focused on food and health sector companies.
The timing reflects broader institutional dynamics across American higher education. UC Davis, like many US universities, is responding to reduced traditional government funding under the current administration by building proprietary investment infrastructure. By taking direct equity positions in spinout companies rather than limiting itself to licensing arrangements, the university can participate in long-term value creation from breakthrough research emerging from its laboratories.
George Baxter, the university's chief innovation and economic development officer, characterized the structural change as foundational: the Investing in the Future of Medicine Fund represents the institution's first formal mechanism for capital deployment into its own companies. This approach positions UC Davis to compete more effectively with peer institutions while leveraging its proximity to the Bay Area venture capital ecosystem, where the university historically maintained informal relationships but did not formally participate as an investor.
The strategy reflects a wider institutional recognition that direct equity participation in spinouts can generate superior returns compared to passive licensing models, while simultaneously strengthening the university's role in the regional innovation economy and creating employment and economic development opportunities in its local market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.